Artal Group S.A. Morphic Holding, Inc. Transaction History

Artal Group S.A.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$26.12 - $34.07 $8.17 Million - $10.7 Million	312,810 Added 14.13%	2,525,998 $86.1 Million
Q1 2024 May 13, 2024	BUY	$26.64 - $40.31 $2 Million - $3.02 Million	75,000 Added 3.51%	2,213,188 $77.9 Million
Q3 2023 Nov 13, 2023	SELL	$21.33 - $59.42 $38,543 - $107,371	-1,807 Reduced 0.08%	2,138,188 $49 Million
Q2 2023 Aug 11, 2023	BUY	$34.33 - $62.11 $11.2 Million - $20.3 Million	326,046 Added 17.97%	2,139,995 $123 Million
Q1 2023 May 12, 2023	SELL	$26.01 - $48.69 $8.74 Million - $16.4 Million	-336,051 Reduced 15.63%	1,813,949 $68.3 Million
Q3 2022 Nov 14, 2022	BUY	$22.23 - $33.37 $11.1 Million - $16.7 Million	500,000 Added 30.3%	2,150,000 $60.8 Million
Q1 2022 May 12, 2022	BUY	$36.25 - $52.02 $2.35 Million - $3.38 Million	64,951 Added 4.1%	1,650,000 $66.2 Million
Q3 2021 Nov 12, 2021	SELL	$53.61 - $67.5 $12.6 Million - $15.8 Million	-234,137 Reduced 12.87%	1,585,049 $89.8 Million
Q1 2021 May 14, 2021	BUY	$29.77 - $84.85 $4.99 Million - $14.2 Million	167,500 Added 10.14%	1,819,186 $115 Million
Q3 2020 Nov 13, 2020	SELL	$22.51 - $30.11 $393,925 - $526,925	-17,500 Reduced 1.05%	1,651,686 $45.2 Million
Q2 2020 Aug 14, 2020	SELL	$12.65 - $29.57 $1.9 Million - $4.44 Million	-150,000 Reduced 8.25%	1,669,186 $45.2 Million
Q3 2019 Nov 14, 2019	BUY	$17.46 - $29.05 $23 Million - $38.3 Million	1,319,186 Added 263.84%	1,819,186 $32.9 Million
Q2 2019 Aug 09, 2019	BUY	$18.0 - $19.82 $9 Million - $9.91 Million	500,000 New	500,000 $9.91 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.